Clinical Trials for Prinicipal Investigator: Sai-Hong Ignatius Ou

7 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-17-100 A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RET mutated thyroid cancer Open
UCI-17-101 A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) Open
UCI-17-61 [EXEMPT - RETROSPECTIVE CHART REVIEW] Retrospective survival analysis among patients with non-small cell lung cancer harboring MET exon 14 mutations Open
UCI-17-81 [EXEMPTED-EXPANDED ACCESS] An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations Open
UCI-18-18 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) Open